Cargando…
Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial
The effects of dapagliflozin (DAP) and pioglitazone (PIO) on body weight and glycaemic control were compared in patients with type 2 diabetes mellitus. Seventy‐one patients on PIO were either switched to DAP (n = 36) at 5 mg per day or continued on PIO (n = 35). Primary endpoints were superiority of...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587523/ https://www.ncbi.nlm.nih.gov/pubmed/30311367 http://dx.doi.org/10.1111/dom.13557 |
_version_ | 1783429085017407488 |
---|---|
author | Cho, Kyu Yong Nakamura, Akinobu Omori, Kazuno Takase, Takahiro Miya, Aika Manda, Naoki Kurihara, Yoshio Aoki, Shin Atsumi, Tatsuya Miyoshi, Hideaki |
author_facet | Cho, Kyu Yong Nakamura, Akinobu Omori, Kazuno Takase, Takahiro Miya, Aika Manda, Naoki Kurihara, Yoshio Aoki, Shin Atsumi, Tatsuya Miyoshi, Hideaki |
author_sort | Cho, Kyu Yong |
collection | PubMed |
description | The effects of dapagliflozin (DAP) and pioglitazone (PIO) on body weight and glycaemic control were compared in patients with type 2 diabetes mellitus. Seventy‐one patients on PIO were either switched to DAP (n = 36) at 5 mg per day or continued on PIO (n = 35). Primary endpoints were superiority of body weight loss and non‐inferiority of HbA1c level after 24 weeks with DAP. Body weight decrease was greater with DAP than with PIO (75.3 ± 14.9 to 71.3 ± 15.1 kg vs. 74.7 ± 13.8 to 75.2 ± 13.9 kg; P < 0.01). Change in the HbA1c level was comparable (P = 0.64). The level of N‐terminal prohormone of brain natriuretic peptide (NT‐proBNP) and urinary albumin : creatinine ratio (ACR) decreased only with DAP (NT‐proBNP, P < 0.01; ACR, P = 0.02), and the change in NT‐proBNP correlated negatively with baseline NT‐proBNP level (ρ = −0.68, P < 0.01) and log‐converted ACR (ρ = −0.35, P < 0.05). DAP promotes body weight loss in type 2 diabetes mellitus and may decrease fluid retention, thus reducing the occurrence of cardiovascular events. |
format | Online Article Text |
id | pubmed-6587523 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-65875232019-07-02 Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial Cho, Kyu Yong Nakamura, Akinobu Omori, Kazuno Takase, Takahiro Miya, Aika Manda, Naoki Kurihara, Yoshio Aoki, Shin Atsumi, Tatsuya Miyoshi, Hideaki Diabetes Obes Metab Brief Reports The effects of dapagliflozin (DAP) and pioglitazone (PIO) on body weight and glycaemic control were compared in patients with type 2 diabetes mellitus. Seventy‐one patients on PIO were either switched to DAP (n = 36) at 5 mg per day or continued on PIO (n = 35). Primary endpoints were superiority of body weight loss and non‐inferiority of HbA1c level after 24 weeks with DAP. Body weight decrease was greater with DAP than with PIO (75.3 ± 14.9 to 71.3 ± 15.1 kg vs. 74.7 ± 13.8 to 75.2 ± 13.9 kg; P < 0.01). Change in the HbA1c level was comparable (P = 0.64). The level of N‐terminal prohormone of brain natriuretic peptide (NT‐proBNP) and urinary albumin : creatinine ratio (ACR) decreased only with DAP (NT‐proBNP, P < 0.01; ACR, P = 0.02), and the change in NT‐proBNP correlated negatively with baseline NT‐proBNP level (ρ = −0.68, P < 0.01) and log‐converted ACR (ρ = −0.35, P < 0.05). DAP promotes body weight loss in type 2 diabetes mellitus and may decrease fluid retention, thus reducing the occurrence of cardiovascular events. Blackwell Publishing Ltd 2018-11-08 2019-03 /pmc/articles/PMC6587523/ /pubmed/30311367 http://dx.doi.org/10.1111/dom.13557 Text en © 2018 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Brief Reports Cho, Kyu Yong Nakamura, Akinobu Omori, Kazuno Takase, Takahiro Miya, Aika Manda, Naoki Kurihara, Yoshio Aoki, Shin Atsumi, Tatsuya Miyoshi, Hideaki Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial |
title | Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial |
title_full | Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial |
title_fullStr | Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial |
title_full_unstemmed | Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial |
title_short | Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial |
title_sort | effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: an open‐label, prospective, randomized, parallel‐group comparison trial |
topic | Brief Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587523/ https://www.ncbi.nlm.nih.gov/pubmed/30311367 http://dx.doi.org/10.1111/dom.13557 |
work_keys_str_mv | AT chokyuyong effectofswitchingfrompioglitazonetothesodiumglucosecotransporter2inhibitordapagliflozinonbodyweightandmetabolismrelatedfactorsinpatientswithtype2diabetesmellitusanopenlabelprospectiverandomizedparallelgroupcomparisontrial AT nakamuraakinobu effectofswitchingfrompioglitazonetothesodiumglucosecotransporter2inhibitordapagliflozinonbodyweightandmetabolismrelatedfactorsinpatientswithtype2diabetesmellitusanopenlabelprospectiverandomizedparallelgroupcomparisontrial AT omorikazuno effectofswitchingfrompioglitazonetothesodiumglucosecotransporter2inhibitordapagliflozinonbodyweightandmetabolismrelatedfactorsinpatientswithtype2diabetesmellitusanopenlabelprospectiverandomizedparallelgroupcomparisontrial AT takasetakahiro effectofswitchingfrompioglitazonetothesodiumglucosecotransporter2inhibitordapagliflozinonbodyweightandmetabolismrelatedfactorsinpatientswithtype2diabetesmellitusanopenlabelprospectiverandomizedparallelgroupcomparisontrial AT miyaaika effectofswitchingfrompioglitazonetothesodiumglucosecotransporter2inhibitordapagliflozinonbodyweightandmetabolismrelatedfactorsinpatientswithtype2diabetesmellitusanopenlabelprospectiverandomizedparallelgroupcomparisontrial AT mandanaoki effectofswitchingfrompioglitazonetothesodiumglucosecotransporter2inhibitordapagliflozinonbodyweightandmetabolismrelatedfactorsinpatientswithtype2diabetesmellitusanopenlabelprospectiverandomizedparallelgroupcomparisontrial AT kuriharayoshio effectofswitchingfrompioglitazonetothesodiumglucosecotransporter2inhibitordapagliflozinonbodyweightandmetabolismrelatedfactorsinpatientswithtype2diabetesmellitusanopenlabelprospectiverandomizedparallelgroupcomparisontrial AT aokishin effectofswitchingfrompioglitazonetothesodiumglucosecotransporter2inhibitordapagliflozinonbodyweightandmetabolismrelatedfactorsinpatientswithtype2diabetesmellitusanopenlabelprospectiverandomizedparallelgroupcomparisontrial AT atsumitatsuya effectofswitchingfrompioglitazonetothesodiumglucosecotransporter2inhibitordapagliflozinonbodyweightandmetabolismrelatedfactorsinpatientswithtype2diabetesmellitusanopenlabelprospectiverandomizedparallelgroupcomparisontrial AT miyoshihideaki effectofswitchingfrompioglitazonetothesodiumglucosecotransporter2inhibitordapagliflozinonbodyweightandmetabolismrelatedfactorsinpatientswithtype2diabetesmellitusanopenlabelprospectiverandomizedparallelgroupcomparisontrial |